Skip to main content
. Author manuscript; available in PMC: 2012 Apr 1.
Published in final edited form as: Pain. 2011 Apr;152(4):878–887. doi: 10.1016/j.pain.2011.01.001

Figure 2.

Figure 2

Figure 2

Figure 2

Antinociceptive effects of imidazole-containing (“azole”) anti-fungal P450 inhibitors. Subjects were baseline (BL) tested, received an icv injection of drug (dose given in nmol) or vehicle, and were re-tested at the post-icv times shown (A, abscissa). Ordinate shows TF response latencies (sec, mean ± SEM) for the number of subjects given in parentheses. B) Dose-response curves are shown for TF latencies taken 11 min after injection. Abscissa is dose of drug (nmol, icv). Data from vehicle and 11 min groups in B are reproduced from A. C) Effects of naltrexone on azole-induced antinociception. Subjects were BL tested as in A, received naltrexone (5 mg/kg, i.p.) or saline, and were re-tested 15 min later. Nineteen min after i.p. injection, subjects received the icv treatment shown (abscissa, dose in nmol). Ordinate shows TF response latencies 11 min post-icv azole treatment for the number of subjects indicated in each group. Rats receiving icv DMSO (some of which also received ip saline) served as the Vehicle group in A-C. The azole treatment groups in A and B included data from respective ip saline-treated subjects shown in C. . *, **P< 0.05, 0.01 vs vehicle; ++P<0.01 vs. saline-sulconazole.